{"id":"exenatide-once-weekly","safety":{"commonSideEffects":[{"rate":"20–40","effect":"Nausea"},{"rate":"5–15","effect":"Vomiting"},{"rate":"10–20","effect":"Diarrhea"},{"rate":"5–15","effect":"Constipation"},{"rate":"5–10","effect":"Injection site reactions"},{"rate":"5–10","effect":"Hypoglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Exenatide binds to and activates GLP-1 receptors on pancreatic beta cells, enhancing glucose-dependent insulin secretion. It also inhibits glucagon secretion when blood glucose is elevated and delays gastric emptying, reducing postprandial glucose spikes. The once-weekly formulation uses extended-release microsphere technology to provide sustained drug delivery over seven days.","oneSentence":"Exenatide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion, suppress glucagon, and slow gastric emptying in response to blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:58.227Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05610800","phase":"PHASE2","title":"Exenatide for Smoking Cessation and Prevention of Weight Gain","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2022-12-07","conditions":"Smoking Cessation, Weight Gain","enrollment":140},{"nctId":"NCT06252623","phase":"PHASE1","title":"Exenatide For Reducing the Reinforcing Effects of Cocaine","status":"WITHDRAWN","sponsor":"Christopher D. Verrico","startDate":"2024-08-01","conditions":"Cocaine Use Disorder","enrollment":""},{"nctId":"NCT05356104","phase":"PHASE2","title":"GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2022-05-25","conditions":"Cerebral Small Vessel Disease","enrollment":110},{"nctId":"NCT02251431","phase":"PHASE3","title":"Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2015-11","conditions":"Type 2 Diabetes Mellitus, Chronic Kidney Disease, Left Ventricular Diastolic Dysfunction","enrollment":57},{"nctId":"NCT02586831","phase":"PHASE1, PHASE2","title":"Diabetes Islet Preservation Immune Treatment","status":"WITHDRAWN","sponsor":"Camillo Ricordi and Jay Skyler","startDate":"2024-06-01","conditions":"Diabetes Mellitus, Type 1, Hypoglycemia, Autoimmune Diseases","enrollment":""},{"nctId":"NCT04520490","phase":"PHASE3","title":"Brain Activation and Satiety in Children 2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seattle Children's Hospital","startDate":"2021-01-28","conditions":"Childhood Obesity","enrollment":63},{"nctId":"NCT06257966","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Dongfang Biotech Co., Ltd.","startDate":"2024-07-17","conditions":"Type2 Diabetes Mellitus","enrollment":600},{"nctId":"NCT04431713","phase":"PHASE2","title":"Exenatide Once-weekly as a Treatment for Multiple System Atrophy","status":"COMPLETED","sponsor":"University College, London","startDate":"2020-09-16","conditions":"Multiple System Atrophy","enrollment":50},{"nctId":"NCT06247748","phase":"PHASE1","title":"Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects","status":"COMPLETED","sponsor":"Beijing Dongfang Biotech Co., Ltd.","startDate":"2023-10-19","conditions":"Diabetes Mellitus, Type 2, Overweight","enrollment":28},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT04232969","phase":"PHASE3","title":"Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease","status":"UNKNOWN","sponsor":"University College, London","startDate":"2020-01-20","conditions":"Parkinson's Disease","enrollment":194},{"nctId":"NCT04504396","phase":"PHASE3","title":"Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy","status":"COMPLETED","sponsor":"PegBio Co., Ltd.","startDate":"2020-06-23","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":620},{"nctId":"NCT04504370","phase":"PHASE3","title":"Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects","status":"COMPLETED","sponsor":"PegBio Co., Ltd.","startDate":"2020-04-27","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":273},{"nctId":"NCT02981069","phase":"PHASE4","title":"Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2017-12-15","conditions":"Diabetes Mellitus, Type 2","enrollment":90},{"nctId":"NCT02621489","phase":"PHASE4","title":"Effects on Re-endothelialisation With Bydureon Treatment in Type 2 Diabetes Subjects","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2015-12","conditions":"Atherosclerosis, Diabetes, Restenosis","enrollment":38},{"nctId":"NCT03456687","phase":"PHASE1","title":"Effects of Exenatide on Motor Function and the Brain","status":"COMPLETED","sponsor":"University of Florida","startDate":"2018-06-05","conditions":"Parkinson's Disease","enrollment":5},{"nctId":"NCT04305002","phase":"PHASE2","title":"Exenatide Treatment in Parkinson's Disease","status":"UNKNOWN","sponsor":"Center for Neurology, Stockholm","startDate":"2020-01-21","conditions":"Parkinson Disease","enrollment":60},{"nctId":"NCT04941521","phase":"PHASE1, PHASE2","title":"Exenatide for Treating Cocaine Use Disorder","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2021-06-24","conditions":"Cocaine Use Disorder","enrollment":3},{"nctId":"NCT02794402","phase":"PHASE2","title":"Double-blinded, 6 Months Study With Bydureon® or Placebo in Adolescents With Obesity to Explore Changes in BMI","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2015-09","conditions":"Obesity","enrollment":44},{"nctId":"NCT02664441","phase":"PHASE3","title":"Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity","status":"COMPLETED","sponsor":"Seattle Children's Hospital","startDate":"2016-03","conditions":"Hypothalamic Obesity","enrollment":42},{"nctId":"NCT03007329","phase":"PHASE4","title":"Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2017-03-08","conditions":"Steatosis, Liver, Type2 Diabetes","enrollment":34},{"nctId":"NCT02417142","phase":"PHASE4","title":"Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia","status":"COMPLETED","sponsor":"University of Massachusetts, Worcester","startDate":"2014-09","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":70},{"nctId":"NCT01554618","phase":"PHASE3","title":"Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-12-02","conditions":"Children and Adolescent With Type 2 Diabetes","enrollment":84},{"nctId":"NCT03970044","phase":"PHASE4","title":"Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.","status":"COMPLETED","sponsor":"Consano Clinical Research, LLC","startDate":"2019-07-02","conditions":"Diabetes Mellitus, Type 2","enrollment":67},{"nctId":"NCT02847403","phase":"PHASE3","title":"Long-acting Exenatide and Cognitive Decline in Dysglycemic Patients","status":"UNKNOWN","sponsor":"Azienda Ospedaliero-Universitaria di Parma","startDate":"2016-02","conditions":"Dysglycemia, Cognitive Deficit","enrollment":40},{"nctId":"NCT03232112","phase":"PHASE2","title":"Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?","status":"COMPLETED","sponsor":"Anders Fink-Jensen, MD, DMSci","startDate":"2017-08-07","conditions":"Alcohol Dependence, in Remission, Addiction, Alcohol","enrollment":152},{"nctId":"NCT02119819","phase":"PHASE2","title":"A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes","status":"COMPLETED","sponsor":"OPKO Health, Inc.","startDate":"2014-04","conditions":"Diabetes Mellitus, Type 2","enrollment":420},{"nctId":"NCT04269642","phase":"PHASE2","title":"SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease","status":"UNKNOWN","sponsor":"Peptron, Inc.","startDate":"2020-03-19","conditions":"Early Parkinson's Disease","enrollment":99},{"nctId":"NCT03671733","phase":"PHASE3","title":"Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2018-09-01","conditions":"Obesity","enrollment":150},{"nctId":"NCT02635386","phase":"PHASE3","title":"EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)","status":"COMPLETED","sponsor":"Woman's","startDate":"2016-03-22","conditions":"Polycystic Ovary Syndrome, Obesity","enrollment":119},{"nctId":"NCT02975297","phase":"PHASE1, PHASE2","title":"Exenatide Once Weekly for Smoking Cessation","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2016-07","conditions":"Smoking Cessation","enrollment":84},{"nctId":"NCT02793154","phase":"PHASE4","title":"An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2016-09-26","conditions":"Diabetes Mellitus, Type 2","enrollment":4},{"nctId":"NCT04001231","phase":"PHASE1","title":"Study of Exenatide Once-Weekly Suspension in Chinese Patients With Type 2 Diabetes Mellitus","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2020-06-30","conditions":"Type 2 Diabetes","enrollment":""},{"nctId":"NCT03419624","phase":"PHASE3","title":"The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients","status":"TERMINATED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2018-02-19","conditions":"Obesity, Diabetes Mellitus, Type 2","enrollment":13},{"nctId":"NCT03444142","phase":"PHASE4","title":"Effect of Exenatide LAR or Dulaglutide on the Variability of 24-hour Heart Rate and Blood Pressure in Type 2 Diabetes","status":"UNKNOWN","sponsor":"University of Guadalajara","startDate":"2017-11-17","conditions":"Diabetes Mellitus, Type 2","enrollment":30},{"nctId":"NCT02072096","phase":"PHASE4","title":"A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2014-02","conditions":"Diabetes Mellitus, Type 2","enrollment":192},{"nctId":"NCT02020616","phase":"PHASE1, PHASE2","title":"A Study of the Safety and Effectiveness of LY3053102 in Participants With Type 2 Diabetes","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2013-12","conditions":"Type 2 Diabetes Mellitus","enrollment":60},{"nctId":"NCT03672604","phase":"PHASE1","title":"A Phase 1 Study to Assess the Safety of NLY01 in Healthy Subjects","status":"COMPLETED","sponsor":"Neuraly, Inc.","startDate":"2018-09-19","conditions":"Safety and Tolerability in Healthy Volunteers","enrollment":96},{"nctId":"NCT02303730","phase":"PHASE4","title":"Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes","status":"COMPLETED","sponsor":"Fudan University","startDate":"2015-03","conditions":"Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease","enrollment":76},{"nctId":"NCT04029272","phase":"PHASE4","title":"Metformin vs Metformin Combined With GLP-1RA (Glucagon-like Peptide 1 Receptor Agonist) on Overweight/Obese PCOS Patients","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2019-07-20","conditions":"Polycystic Ovary Syndrome","enrollment":80},{"nctId":"NCT01885208","phase":"PHASE3","title":"Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-12-02","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":813},{"nctId":"NCT02533453","phase":"PHASE4","title":"A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-01-28","conditions":"Type 2 Diabetes Mellitus","enrollment":110},{"nctId":"NCT03959865","phase":"","title":"GLP-1 REceptor Agonists and Real World EvIdeNce","status":"UNKNOWN","sponsor":"University of Padova","startDate":"2018-12-19","conditions":"Type 2 Diabetes","enrollment":6000},{"nctId":"NCT02229383","phase":"PHASE3","title":"Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-09-06","conditions":"Diabetes Mellitus","enrollment":464},{"nctId":"NCT02229396","phase":"PHASE3","title":"Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-09-04","conditions":"Diabetes Mellitus","enrollment":695},{"nctId":"NCT01144338","phase":"PHASE3","title":"Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-06-18","conditions":"Type 2 Diabetes Mellitus","enrollment":14752},{"nctId":"NCT01652716","phase":"PHASE3","title":"Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-01","conditions":"Diabetes Mellitus, Type 2","enrollment":377},{"nctId":"NCT02162550","phase":"PHASE4","title":"Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Phoenix VA Health Care System","startDate":"2014-06","conditions":"Type 2 Diabetes","enrollment":148},{"nctId":"NCT02917057","phase":"","title":"Subanalyses of Elderly Type 2 Diabetes Patients or Type 2 Diabetes Patients With Renal Impairment","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-08-01","conditions":"Type 2 Diabetes","enrollment":6024},{"nctId":"NCT02843399","phase":"","title":"Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-08-15","conditions":"Diabetes Mellitus Type 2","enrollment":15498},{"nctId":"NCT02987348","phase":"","title":"Clinical Outcomes of Exenatide Versus Basal Insulin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-06-30","conditions":"Type 2 Diabetes","enrollment":18000},{"nctId":"NCT02974244","phase":"","title":"Comparison of the Effectiveness and Tolerability of Exenatide Once-weekly Compared to Basal Insulins","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-10-28","conditions":"Type 2 Diabetes","enrollment":7000},{"nctId":"NCT03059719","phase":"PHASE1","title":"Clinical Trial for PB-119 in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"PegBio Co., Ltd.","startDate":"2015-04-08","conditions":"Type II Diabetes Mellitus","enrollment":36},{"nctId":"NCT02084251","phase":"PHASE1","title":"Clinical Trial for PB-119 in Healthy Subjects (Phase I)","status":"COMPLETED","sponsor":"PegBio Co., Ltd.","startDate":"2014-02","conditions":"Type II Diabetes","enrollment":70},{"nctId":"NCT02288273","phase":"PHASE4","title":"Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-12","conditions":"Type 2 Diabetes","enrollment":239},{"nctId":"NCT01971242","phase":"PHASE2","title":"Trial of Exenatide for Parkinson's Disease","status":"COMPLETED","sponsor":"University College, London","startDate":"2014-06","conditions":"Parkinson's Disease","enrollment":60},{"nctId":"NCT02313220","phase":"PHASE2","title":"Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body Weight","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2014-12","conditions":"Obesity","enrollment":50},{"nctId":"NCT02380521","phase":"PHASE4","title":"Exenatide Once Weekly, Cardiovascular Risk and Type-2 Diabetes","status":"COMPLETED","sponsor":"University of Palermo","startDate":"2015-01","conditions":"Type 2 Diabetes Mellitus","enrollment":60},{"nctId":"NCT00717457","phase":"PHASE3","title":"A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-07","conditions":"Diabetes Mellitus Type 2","enrollment":1189},{"nctId":"NCT00803920","phase":"","title":"Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes Taking Twice-Daily Exenatide or Once-Weekly Exenatide","status":"COMPLETED","sponsor":"HealthPartners Institute","startDate":"2006-12","conditions":"Type 2 Diabetes Mellitus","enrollment":8},{"nctId":"NCT00806520","phase":"","title":"Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control","status":"COMPLETED","sponsor":"HealthPartners Institute","startDate":"2008-04","conditions":"Type 2 Diabetes","enrollment":16},{"nctId":"NCT00894322","phase":"PHASE1, PHASE2","title":"A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-04","conditions":"Type 2 Diabetes Mellitus","enrollment":65},{"nctId":"NCT00308139","phase":"PHASE3","title":"Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-04","conditions":"Type 2 Diabetes Mellitus","enrollment":303},{"nctId":"NCT01104701","phase":"PHASE2","title":"A Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-05","conditions":"Type 2 Diabetes","enrollment":121},{"nctId":"NCT01652729","phase":"PHASE3","title":"Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-02","conditions":"Diabetes Type 2","enrollment":365},{"nctId":"NCT01794429","phase":"PHASE3","title":"Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue","status":"COMPLETED","sponsor":"Bjorn H. Ebdrup","startDate":"2013-02","conditions":"Obesity, Metabolic Syndrome X, Drug-induced Obesity","enrollment":45},{"nctId":"NCT00935532","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-07","conditions":"Type 2 Diabetes Mellitus","enrollment":427},{"nctId":"NCT00641056","phase":"PHASE3","title":"Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-04","conditions":"Type 2 Diabetes Mellitus","enrollment":467},{"nctId":"NCT00753896","phase":"PHASE3","title":"Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-10","conditions":"Type 2 Diabetes","enrollment":134},{"nctId":"NCT01029886","phase":"PHASE3","title":"Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-01","conditions":"Type 2 Diabetes Mellitus","enrollment":912},{"nctId":"NCT00676338","phase":"PHASE3","title":"Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-11","conditions":"Type 2 Diabetes Mellitus","enrollment":820},{"nctId":"NCT00917267","phase":"PHASE3","title":"A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-07","conditions":"Type 2 Diabetes Mellitus","enrollment":691},{"nctId":"NCT01003184","phase":"PHASE3","title":"Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-10","conditions":"Type 2 Diabetes Mellitus","enrollment":222},{"nctId":"NCT00877890","phase":"PHASE3","title":"A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-03","conditions":"Type 2 Diabetes Mellitus","enrollment":254},{"nctId":"NCT00637273","phase":"PHASE3","title":"A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-01","conditions":"Type 2 Diabetes Mellitus","enrollment":514},{"nctId":"NCT00612794","phase":"PHASE1","title":"A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-09","conditions":"Type 2 Diabetes","enrollment":30},{"nctId":"NCT00103935","phase":"PHASE2","title":"Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-02","conditions":"Type 2 Diabetes Mellitus","enrollment":45},{"nctId":"NCT01507038","phase":"PHASE2","title":"Safety and Efficacy of YH14617 in Diabetes Mellitus","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2011-12","conditions":"Diabetes Mellitus","enrollment":84},{"nctId":"NCT01064687","phase":"PHASE3","title":"A Study in Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-02","conditions":"Diabetes Mellitus, Type 2","enrollment":978}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ANAPHYLACTIC REACTION"}],"_approvalHistory":[],"publicationCount":203,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BYDUREON","long_acting glucagon-like peptide-1 receptor agonist"],"phase":"phase_3","status":"active","brandName":"Exenatide Once Weekly","genericName":"Exenatide Once Weekly","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Exenatide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion, suppress glucagon, and slow gastric emptying in response to blood glucose levels. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}